Top searches

PL

Resources

B2RLaw advises Proteon Pharmaceuticals on a strategic partnership with Skretting

01/02/2021

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry.

The companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.

The Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.

Proteon Pharmaceuticals is a Polish originating biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The Company uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norwegian company, Skretting is the world’s largest producer of feeds for farmed fish. The Company has operations on five continents and produces 2.5 million tonnes of feed annually, for more than sixty species of fish. Skretting has 3,500 employees worldwide. Skretting has an R&D unit known as Skretting Aquaculture Research Centre (ARC) with the main objective to provide research and technical support regarding fish and shrimp feed. It has 140 employees representing 25 nationalities.

B2RLaw’s team advising Proteon Pharmaceuticals was led by Partner George Havaris and included Counsels Paulina Wyrostek and Malwina Niczke – Chmura.

George Havaris advises, “Proteon Pharmaceuticals is a Polish company that is well on the path to being a global leader in its field of operation. Animal health is a little-known industry in the wider public eye. However, animal health is fundamental to the health and well-being of humans. We congratulate Proteon and Skretting on this exciting Partnership and we look forward to continuing our support to Proteon on its growth path”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

27/08/2021

B2RLaw advises early stage technology company The Village Network on financing received by Movens Capital

B2RLaw has advised The Village Network, a Polish company creating Wioski.co, which is run by three female entrepreneurs, and supports […]

MORE
11/08/2021

B2RLaw further strengthens Real Estate Practice to create all-star team

B2RLaw has appointed Andrzej Zając as Counsel to its Real Estate Practice. Andrzej is a next generation leader with a […]

MORE
24/06/2021

B2RLaw advises Kennet Partners and Digital+ Partners on their USD 30 million equity investment in eStoreMedia

B2RLaw has advised growth equity investors Kennet Partners and Digital+ Partners on their USD 30 million equity investment in Polish […]

MORE
14/06/2021

B2RLaw named Venture Capital Legal Advisor of the Year at the PSIK Awards 2021

B2RLaw is celebrating after being awarded Venture Capital Legal Advisor of the Year at the Polish Private Equity and Venture […]

MORE
09/06/2021

Edyta Zalewska joins B2RLaw’s Partnership, and six lawyers are promoted

B2RLaw has announced Edyta Zalewska as Partner in its 2021 promotion round, effective as of 1st May 2021. B2RLaw is also […]

MORE
11/05/2021

B2RLaw shortlisted as a finalist of the PSIK Awards 2021 for Venture Capital Legal Advisor of the Year

B2RLaw is pleased to advise that it has been selected as a finalist of the PSIK Awards 2021 for Venture […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close